You just read:

Merck KGaA, Darmstadt, Germany, Announces Positive Phase IIB Results for Evobrutinib in Relapsing Multiple Sclerosis

News provided by

Merck KGaA, Darmstadt, Germany

Mar 07, 2018, 09:55 ET